Data shows both pre- and post-institution agreements at highest levels since 2014 and comes against backdrop of dramatic fall in new IPR filings
Pharma patent litigation settlements involving the transfer of “anything of value” to the generic are now presumed anti-competitive under Golden State law
Samsung, Sony and Google are among the companies who are shifting smartphone production from China to Southeast Asia
A recent announcement is the first time that the Finnish company has drawn attention to the release of SEPs and comes after months of stories about Chinese dominance of the technology
Invalidation efforts in both China and the United States have come up short as the US chip giant faces Chinese infringement claims
Eight Chinese entities – including leaders in AI, facial recognition and data forensics - added to Bureau of Industrial Security entity list
New role has the potential to deliver results that will enhance internal processes, improve quality, lower costs and help recover lost US influence in the international IP arena
Korean telco has started selling patents to other operating companies in the last two years, after previous deals focused on the NPE sector
Investing in IP may be necessary for early-stage businesses, but there are plenty of circumstances when the money is better spent elsewhere
Shenzhen Transsion, the dominant mobile phone seller on the African continent, said to have come into IP conflict with Huawei shortly before going public
Taiwanese maker of smartphone lenses is now wielding patents against not just a rival supplier but its end customer HP
Taiwan’s Personal Genomics is going after an acquisition target of Illumina, the top player in the sequencing space
The company wants to shift disputes to its home jurisdiction and persuade courts there to set a low, China-specific rate
Akorn Inc’s failure to make its case against Allergan and Duke is a reminder that challenging life sciences patentees remains a tough task
Concern about parting with its image sensor business and IP portfolio illustrates a problem for Japanese companies seeking to restructure
